Fusen Pharm Calls 9 July 2026 EGM to Approve RMB 300.00 Million Capital Injection into Henan Subsidiary

Bulletin Express

Jun 23

Fusen Pharmaceutical Company Limited (Fusen Pharm, 01652) has convened an Extraordinary General Meeting (EGM) for 2:00 p.m. on 9 July 2026 at The Center, 99 Queen’s Road Central, Hong Kong. Shareholders will vote on a single ordinary resolution authorising a RMB 300.00 million capital increase for its wholly owned subsidiary, Henan Fusen Pharmaceutical Company Limited.

Key terms of the proposal • Capital Increase Agreement date: 18 June 2026 • Total subscription: RMB 300.00 million in newly issued registered capital of Henan Fusen Pharmaceutical Company Limited • Investors: Nanyang Industrial Investment Health Industry Group Co., Ltd. and Henan Xisheng Industrial Development Co., Ltd. • Transaction parties also include Nanyang Hengsheng Enterprise Management Services Limited and Wealth Depot (Hong Kong) Limited, reflecting a multilateral structure to facilitate the investment.

Shareholder logistics • Record date: 9 July 2026 • Register closure: 6–9 July 2026 (both days inclusive); no share transfers processed during this period • Proxy submissions: due by 2:00 p.m. on 7 July 2026 at Computershare Hong Kong Investor Services

If approved, Fusen Pharm’s directors will be authorised to execute all necessary documents and actions to complete the capital increase and ancillary arrangements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/1132248963"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132248963\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132248963?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 06:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132248963","market":"hk","top_or_hot":-1,"title":"Fusen Pharm Calls 9 July 2026 EGM to Approve RMB 300.00 Million Capital Injection into Henan Subsidiary","media":"Bulletin Express","content":"<p>Fusen Pharmaceutical Company Limited (Fusen Pharm, 01652) has convened an Extraordinary General Meeting (EGM) for 2:00 p.m. on 9 July 2026 at The Center, 99 Queen’s Road Central, Hong Kong. Shareholders will vote on a single ordinary resolution authorising a RMB 300.00 million capital increase for its wholly owned subsidiary, Henan Fusen Pharmaceutical Company Limited.</p>\n<p>Key terms of the proposal  \n• Capital Increase Agreement date: 18 June 2026  \n• Total subscription: RMB 300.00 million in newly issued registered capital of Henan Fusen Pharmaceutical Company Limited  \n• Investors: Nanyang Industrial Investment Health Industry Group Co., Ltd. and Henan Xisheng Industrial Development Co., Ltd.  \n• Transaction parties also include Nanyang Hengsheng Enterprise Management Services Limited and Wealth Depot (Hong Kong) Limited, reflecting a multilateral structure to facilitate the investment.</p>\n<p>Shareholder logistics  \n• Record date: 9 July 2026  \n• Register closure: 6–9 July 2026 (both days inclusive); no share transfers processed during this period  \n• Proxy submissions: due by 2:00 p.m. on 7 July 2026 at Computershare Hong Kong Investor Services</p>\n<p>If approved, Fusen Pharm’s directors will be authorised to execute all necessary documents and actions to complete the capital increase and ancillary arrangements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fusen Pharm Calls 9 July 2026 EGM to Approve RMB 300.00 Million Capital Injection into Henan Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFusen Pharm Calls 9 July 2026 EGM to Approve RMB 300.00 Million Capital Injection into Henan Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fusen Pharmaceutical Company Limited (Fusen Pharm, 01652) has convened an Extraordinary General Meeting (EGM) for 2:00 p.m. on 9 July 2026 at The Center, 99 Queen’s Road Central, Hong Kong. Shareholders will vote on a single ordinary resolution authorising a RMB 300.00 million capital increase for its wholly owned subsidiary, Henan Fusen Pharmaceutical Company Limited.</p>\n<p>Key terms of the proposal  \n• Capital Increase Agreement date: 18 June 2026  \n• Total subscription: RMB 300.00 million in newly issued registered capital of Henan Fusen Pharmaceutical Company Limited  \n• Investors: Nanyang Industrial Investment Health Industry Group Co., Ltd. and Henan Xisheng Industrial Development Co., Ltd.  \n• Transaction parties also include Nanyang Hengsheng Enterprise Management Services Limited and Wealth Depot (Hong Kong) Limited, reflecting a multilateral structure to facilitate the investment.</p>\n<p>Shareholder logistics  \n• Record date: 9 July 2026  \n• Register closure: 6–9 July 2026 (both days inclusive); no share transfers processed during this period  \n• Proxy submissions: due by 2:00 p.m. on 7 July 2026 at Computershare Hong Kong Investor Services</p>\n<p>If approved, Fusen Pharm’s directors will be authorised to execute all necessary documents and actions to complete the capital increase and ancillary arrangements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森药业","start_time":0,"source_url":"","article_id":"1132248963","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132248963","pubTimestamp":1782168383,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fusen Pharmaceutical Company Limited (Fusen Pharm, 01652) has convened an Extraordinary General Meeting (EGM) for 2:00 p.m. on 9 July 2026 at The Center, 99 Queen’s Road Central, Hong Kong....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业"},"translate_title":"福森药业评级2026年7月9日临时股东大会批准向河南省附属公司注资人民币300,000.00万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"Fusen Pharmaceutical Company Limited (Fusen Pharm, 01652) has convened an Extraordinary General Meeting (EGM) for 2:00 p.m. on 9 July 2026 at The Center, 99 Queen’s Road Central, Hong Kong. Shareholders will vote on a single ordinary resolution authorising a RMB 300.00 million capital increase for its wholly owned subsidiary, Henan Fusen Pharmaceutical Company Limited.\nKey terms of the proposal  \n• Capital Increase Agreement date: 18 June 2026  \n• Total subscription: RMB 300.00 million in newly issued registered capital of Henan Fusen Pharmaceutical Company Limited  \n• Investors: Nanyang Industrial Investment Health Industry Group Co., Ltd. and Henan Xisheng Industrial Development Co., Ltd.  \n• Transaction parties also include Nanyang Hengsheng Enterprise Management Services Limited and Wealth Depot (Hong Kong) Limited, reflecting a multilateral structure to facilitate the investment.\nShareholder logistics  \n• Record date: 9 July 2026  \n• Register closure: 6–9 July 2026 (both days inclusive); no share transfers processed during this period  \n• Proxy submissions: due by 2:00 p.m. on 7 July 2026 at Computershare Hong Kong Investor Services\nIf approved, Fusen Pharm’s directors will be authorised to execute all necessary documents and actions to complete the capital increase and ancillary arrangements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}